Neumora Therapeutics
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Neumora Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Neumora Therapeutics: 7 sponsored US clinical trials, 3 recruiting.
Neumora Therapeutics sponsors 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 4 completed. 4 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Major Depressive Disorder, with 3 trials.
Upper-quartile sponsor footprint
Neumora Therapeutics sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
NCT06058039
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
NCT06058013
Study to Assess the Safety and Effectiveness of NMRA-335140-501
NCT06029439
Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease
NCT06546995
To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.
NCT06429722
Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
NCT06029426
Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo
NCT04221230
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Phase 3 | 4 |
What is open in the Neumora Therapeutics pipeline
3 recruiting of 7 indexed (43% open); 4 completed (57%).
Phase mix: 4 late (III/IV) vs 3 early (I/II) (balanced across stages).
Top condition: Major Depressive Disorder (3 trials), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Neumora Therapeutics: open-pipeline peers nationwide
Peers matched on 7 registered trials and 43% open enrollment, not the therapeutic-area sidebar.
Neumora Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 43% open enrollment (± trial volume)
- Alphatec Spine · 43% recruiting · 7 trials
- Clarity Pharmaceuticals · 43% recruiting · 7 trials
- Colorado Center for Reproductive Medicine · 43% recruiting · 7 trials
- David Moss · 43% recruiting · 7 trials
Related
What to do with this Neumora Therapeutics page
7 registered trials is a research-attention snapshot, not an endorsement of Neumora Therapeutics or any single study.
- 3 of Neumora Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Major Depressive Disorder is the condition Neumora Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Major Depressive Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Neumora Therapeutics pipeline card: 7 registered trials from official public datasets.Report a data error.